MARKET

CRBP

CRBP

Corbus Pharms
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.020
-0.090
-8.11%
After Hours: 1.030 +0.01 +0.98% 19:57 10/19 EDT
OPEN
1.104
PREV CLOSE
1.110
HIGH
1.110
LOW
1.020
VOLUME
5.46M
TURNOVER
--
52 WEEK HIGH
9.78
52 WEEK LOW
1.020
MARKET CAP
83.35M
P/E (TTM)
-0.6085
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Most Heavily Shorted Stocks: October 2020
This article presents a list of stocks with the highest short interest as a percentage of shares outstanding.An unprecedented year amid the COVID-19 pandemic driving historic volatility has represented significant trading opportunities for short-sellers.We analyze key trends and how to best interpret the short interest data.
Seekingalpha · 5d ago
Corbus Pharma plans workforce reduction by 54% to advance clinical programs
Corbus Pharmaceuticals Holdings (CRBP) announces restructuring by reduction its workforce by 54% to reallocate capital to certain clinical and preclinical programs. The company will allocate resources towards its lenabasum clinical
Seekingalpha · 10/08 13:07
Corbus Pharma to ax 54% of workforce in cost-cutting move
Corbus Pharmaceuticals Holdings (CRBP) announces restructuring by reduction its workforce by 54% to reallocate capital to certain clinical and preclinical programs. The company will allocate resources towards its lenabasum clinical
Seekingalpha · 10/08 13:07
Corbus Pharmaceuticals Announces Corporate Restructuring and Pipeline Portfolio Updates
* Company is restructuring with the goal of extending cash runway to mid-2022 * Workforce to be reduced by 54% * Company to focus on completing Phase 3 dermatomyositis study and advancing preclinical pipeline into the clinicNorwood, MA, Oct. 08, 2020 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings
GlobeNewswire · 10/08 13:05
Corbus Stock Down as Lenabasum Fails to Meet Primary Endpoint
Corbus (CRBP) releases disappointing top-line results from its 28-week phase IIb study of lenabasum in patients with cystic fibrosis.
Zacks · 10/07 15:46
The Daily Biotech Pulse: Bristol-Myers Squibb's Lung Cancer Readout, Positive News From Masimo, Integra Lifesciences
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 6)
Benzinga · 10/07 11:30
Mid-Afternoon Market Update: Dow Surges 150 Points; Alteryx Shares Spike Higher
Toward the end of trading Tuesday, the Dow traded up 0.54% to 28,299 while the NASDAQ rose 0.21% to 11,356.01. The S&P also rose, gaining 0.38% to 3,421.68.
Benzinga · 10/06 18:34
Roth Capital cuts target price for Corbus Pharmaceuticals
Roth Capital has lowered price target on Corbus Pharmaceuticals ([[CRBP]] -37.3%) to $1.22 from $3, though rating remains unchanged at Neutral, in reaction to Company's Phase 2 cystic fibrosis study with lenabasum,
Seekingalpha · 10/06 18:26
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of CRBP. Analyze the recent business situations of Corbus Pharms through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 7 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average CRBP stock price target is 6.90 with a high estimate of 27.00 and a low estimate of 1.220.
EPS
Institutional Holdings
Institutions: 193
Institutional Holdings: 46.94M
% Owned: 57.45%
Shares Outstanding: 81.71M
TypeInstitutionsShares
Increased
47
8.93M
New
51
2.99M
Decreased
27
1.61M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-1.82%
Pharmaceuticals & Medical Research
-1.70%
Key Executives
Chairman/Independent Director
Alan Holmer
Chief Executive Officer/Director
Yuval Cohen
Chief Financial Officer
Sean Moran
Executive Director
Sergei Atamas
Chief Operating Officer
Robert Discordia
Other
Craig Millian
Other
Barbara White
Independent Director
Avery Catlin
Independent Director
Rachelle Jacques
Independent Director
John Jenkins
Independent Director
Peter Salzmann
  • Dividends
  • Splits
  • Insider Activity
No Data
  • All
  • Financials
  • Insiders
More
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About CRBP
Corbus Pharmaceuticals Holdings, Inc. is a Phase-III, clinical-stage pharmaceutical company focused on the development and commercialization of novel therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases. The Company operates through developing and commercializing therapeutics to treat rare life-threatening inflammatory fibrotic diseases segment. The Company's lead product candidate, lenabasum, is a novel, synthetic oral endocannabinoid-mimetic drug designed to resolve chronic inflammation and halt fibrotic processes. Lenabasum stimulates the production of Specialized Pro-Resolving Lipid Mediators (SPMs) that act to resolve inflammation, and halt fibrosis by activating endogenous pathways. The Company is developing lenabasum to treat four diseases: systemic sclerosis, cystic fibrosis, diffuse cutaneous, skin-predominant dermatomyositis and systemic lupus erythematosus (SLE).
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Corbus Pharmaceuticals Holdings Inc stock information, including NASDAQ:CRBP real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CRBP stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CRBP stock methods without spending real money on the virtual paper trading platform.